Predictive tumor dosimetry and pharmacokinetic evaluation of [67Cu]Cu-rhPSMA-10.1 and [68Ga]Ga-rhPSMA-10.1 with PET/SPECT MRI in an orthotopic mouse model of glioblastoma

This study demonstrates the translational potential of [⁶⁷Cu]Cu-rhPSMA-10.1 as a targeted radionuclide therapy for PSMA-expressing GBM, supported by predictive PET-based dosimetry using [⁶⁸Ga]Ga-rhPSMA-10.1. Tumor dose estimates derived from PET closely matched those validated by SPECT imaging, indicating strong concordance between prediction and actual uptake. Additionally, IHC confirmed PSMA expression in human GBM vasculature, reinforcing the clinical relevance. These findings highlight the feasibility of integrating a cyclotron-produced ⁶⁷Cu-based theranostic strategy for GBM, enabling personalized, image-guided dosimetry and paving the way for future preclinical efficacy studies and potential clinical translation.